Pomegranates have long been renowned for their benefits to cardiovascular health, yet the precise ways they impact the body remained somewhat obscure. A recent piece of research published in the journal “Antioxidants” has shed light on this topic, highlighting a crucial role played by the gut microbiota in mediating the positive effects of pomegranates.
Cardiovascular conditions, such as atherosclerosis, progress gradually. Fatty deposits accumulate within the arteries, potentially causing inflammation and narrowing the vessels, thereby elevating the danger of heart attacks and strokes. While cholesterol-lowering statins offer assistance, they do not fully mitigate all inherent risks. Consequently, researchers are actively searching for novel, natural agents capable of safeguarding the cardiovascular system.
Particular interest has been directed towards the polyphenols found in pomegranates, especially punicalagin. Previously, it was assumed that this compound acted directly, but it has now been discovered that it is barely metabolized in the bloodstream. Instead, punicalagin undergoes fermentation by microorganisms in the gut, yielding urolithins, which are subsequently absorbed into the circulation.
Researchers determined that urolithin A exerts a particularly potent influence on cells implicated in cardiovascular disease development. In laboratory tests, it was shown to reduce inflammatory responses, alleviate cellular stress, and curb the activity of immune cells that damage the vascular lining.
Studies conducted on animal subjects exhibiting high cholesterol levels demonstrated that urolithin A leads to a reduction in the size of atherosclerotic plaques and enhances their stability, thus lowering the possibility of rupture and acute cardiac episodes. Notably, these beneficial outcomes were observable even without a substantial drop in overall cholesterol levels, suggesting a distinct mechanism of action centered on inflammation suppression and vascular health improvement.
About the Author
